Noveome Biotherapeutics

Executive Summary

Noveome Biotherapeutics is a private biopharmaceutical company advancing ST266, a first-in-class multi-targeted secretome biologic composed of hundreds of biologically active proteins. The product is designed to promote neuroprotection, modulate inflammation, and enhance cell recovery and healing. ST266 is being investigated across ophthalmology, neurology, and dermatology for underserved conditions such as diabetic retinopathy, traumatic brain injury, and chronic wounds. As of early 2026, the company is completing Phase 1 studies to establish safety and preliminary efficacy. With a strong scientific rationale and broad therapeutic potential, Noveome is positioned to address significant unmet medical needs. However, as a private, early-stage entity with limited public data, its near-term success depends on favorable clinical readouts and regulatory advancements.

Upcoming Catalysts (preview)

• TBDPhase 1 top-line results for ST266 in diabetic retinopathy60% success
• TBDInitiation of Phase 2 trial for ST266 in traumatic brain injury50% success
• TBDFDA meeting or Orphan Drug designation for any indication70% success